$7.06 6.6%
CABA Stock Price vs. AI Score (Last 150 days)
Data gathered: July 18

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Cabaletta Bio

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.


Cabaletta Bio
Price $7.06
Target Price Sign up
Volume 765,640
Market Cap $379M
Year Range $7.05 - $25.38
Dividend Yield 0%
Revenue per Employee $70,351
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2406.3M-6.3M-25M-28M-0.510
Q4 '234M5.9M-5.9M-21M-23M-0.460
Q3 '2304.9M-4.9M-16M-19M-0.370
Q2 '2304.1M-4.1M-14M-16M-0.370
Q1 '2304.7M-4.7M-16M-17M-0.450

Insider Transactions View All

Binder Gwendolyn filed to sell 20,000 shares at $20.3.
January 19 '24
Binder Gwendolyn filed to sell 20,700 shares at $19.5.
January 19 '24
Binder Gwendolyn filed to sell 20,000 shares at $22.2.
December 19 '23
Binder Gwendolyn filed to sell 23,132 shares at $21.8.
December 19 '23
Binder Gwendolyn filed to sell 27,458 shares at $17.4.
November 21 '23

What is the Market Cap of Cabaletta Bio?

The Market Cap of Cabaletta Bio is $379M.

How Many People Work at Cabaletta Bio?

As of our latest update, Cabaletta Bio employed approximately 57 people worldwide. However, it's important to note that Cabaletta Bio's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Cabaletta Bio's revenue per employee?

$70,351. To calculate Cabaletta Bio's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Cabaletta Bio?

Currently, the price of one share of Cabaletta Bio stock is $7.06.

How can I analyze the CABA stock price chart for investment decisions?

The CABA stock price chart above provides a comprehensive visual representation of Cabaletta Bio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cabaletta Bio shares. Our platform offers an up-to-date CABA stock price chart, along with technical data analysis and alternative data insights.

Does CABA offer dividends to its shareholders?

As of our latest update, Cabaletta Bio (CABA) does not offer dividends to its shareholders. Investors interested in Cabaletta Bio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Cabaletta Bio?

Some of the similar stocks of Cabaletta Bio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.